Andreia Domnica Tatar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andreia Domnica Tatar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Gherghel
Emergency University Hospital, 050098 Bucharest, Romania
1 shared publication - Anda Baicus
Department of Microbiology, University of Medicine and Pharmacy, Carol Davila, 020021 Bucharest, Romania
1 shared publication - Catalin Cirstoiu
Department of Orthopedics, University of Medicine and Pharmacy, Carol Davila, 020021 Bucharest, Romania
1 shared publication - Corina Silvia Pop
Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
1 shared publication - Diana Gabriela Iacob
Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
1 shared publication - Valentina Daniela Sisu
Department of Microbiology, University of Medicine and Pharmacy, Carol Davila, 020021 Bucharest, Romania
1 shared publication
Latest Publications
- Open Access
- 5 November 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (11) , 1113
In Vitro Activity of Cefiderocol Against Multi-Drug-Resistant Gram-Negative Clinical Isolates in Romania
Background/Objectives: Gram-negative bacteria with acquired carbapenem resistance have become increasingly common in serious infections. This study aimed to evaluate the in vitro activity of cefiderocol against multidrug-resistant Gram-negative clinical isolates collected from a tertiary care hospital in Romania. Methods: A retrospective study (November 2024–February 2025) involving 89 consecutive Multi-Drug Resistant (MDR) Gram-negative isolates, 66 Enterobacterales and 23 non-fermenters (P. aeruginosa, S. maltophilia, A. baumannii), was conducted. Results: Overall, 52.8% of Enterobacterales and P. aeruginosa isolates were susceptible to cefiderocol, with higher susceptibility among Enterobacterales alone (63.6%). Using disk diffusion, 66.3% of all isolates were classified as susceptible to the antibiotic. K. pneumoniae isolates co-harboring NDM and OXA-48 were susceptible in 65.3% of cases, while NDM-only producers were resistant. All P. aeruginosa isolates tested were susceptible to the antibiotic. Susceptibility rates in A. baumannii were lower (68.8%), with variability between testing methods. Conclusions: The presence of NDM-producing isolates with complete resistance to cefiderocol in our study highlights the risk that resistance may spread rapidly once the drug becomes widely used. Cefiderocol may be an effective option for treating MDR bacterial infections, but strict microbiological monitoring remains essential.
- 5 November 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (11) , 1113
Open AccessIn Vitro Activity of Cefiderocol Against Multi-Drug-Resistant Gram-Negative Clinical Isolates in Romania
Background/Objectives: Gram-negative bacteria with acquired carbapenem resistance have become increasingly common in serious infections. This study aimed to evaluate the in vitro activity of cefiderocol against multidrug-resistant Gram-negative clinical isolates collected from a tertiary care hospital in Romania. Methods: A retrospective study (November 2024–February 2025) involving 89 consecutive Multi-Drug Resistant (MDR) Gram-negative isolates, 66 Enterobacterales and 23 non-fermenters (P. aeruginosa, S. maltophilia, A. baumannii), was conducted. Results: Overall, 52.8% of Enterobacterales and P. aeruginosa isolates were susceptible to cefiderocol, with higher susceptibility among Enterobacterales alone (63.6%). Using disk diffusion, 66.3% of all isolates were classified as susceptible to the antibiotic. K. pneumoniae isolates co-harboring NDM and OXA-48 were susceptible in 65.3% of cases, while NDM-only producers were resistant. All P. aeruginosa isolates tested were susceptible to the antibiotic. Susceptibility rates in A. baumannii were lower (68.8%), with variability between testing methods. Conclusions: The presence of NDM-producing isolates with complete resistance to cefiderocol in our study highlights the risk that resistance may spread rapidly once the drug becomes widely used. Cefiderocol may be an effective option for treating MDR bacterial infections, but strict microbiological monitoring remains essential.